NCT06221397 2026-03-16
LEGIT_MC_EVCDA
AI Labs Group S.L
Completed
Clinical Trials
13 trialsNCT01986712 2025-02-13
A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma
St. Luke's Hospital and Health Network, Pennsylvania
Completed
NCT05172232 2025-02-05
AI-DSMM
Linkoeping University
Completed
NCT05954546 2025-02-05
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
Pfizer
Completed
NCT04969419 2025-01-14
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Momentum Data
Completed
NCT02791594 2024-11-08
Imaging FDG Flare in Melanoma
Abramson Cancer Center at Penn Medicine
Completed
NCT01840527 2024-09-04
Utility of Novel BRAF Test for Melanoma
Massachusetts General Hospital
Completed
NCT03709771 2024-01-12
Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease
Vanderbilt University Medical Center
Terminated
NCT02663232 2023-07-03
Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma
Hoffmann-La Roche
Completed
NCT01744860 2016-03-28
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Hoffmann-La Roche
Completed
NCT00749684 2015-10-19
Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)
Merck Sharp & Dohme LLC
Completed
NCT00723710 2015-08-26
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)
Merck Sharp & Dohme LLC
Completed
NCT01387581 2014-11-14
Does the Aid of MelaFind Affect Clinical Management Decisions
MELA Sciences, Inc.
Completed